Neurodegeneration in tauopathies and synucleinopathies
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Neurodegeneration in tauopathies and synucleinopathies |
Type de publication | Journal Article |
Year of Publication | 2016 |
Auteurs | Foguem C., Kamsu-Foguem B. |
Journal | REVUE NEUROLOGIQUE |
Volume | 172 |
Pagination | 709-714 |
Date Published | NOV |
Type of Article | Article |
ISSN | 0035-3787 |
Mots-clés | Alzheimer's disease, Dementia, Dementia with Lewy bodies, neurodegenerative diseases, Parkinson's disease |
Résumé | While increasing life expectancy is a major achievement, the global aging of societies raises a number of medical issues, such as the development of age-related disorders, including neurodegenerative diseases. The three main disease groups constituting the majority of neurodegenerative diseases are tauopathies, alpha-synucleinopathies and diseases due to repetitions of glutamine (including Huntington's disease). In each neurodegenerative disease, the accumulation of one or more aggregated proteins has been identified as the molecular signature of the disease (as seen, for example, in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, amyotrophic lateral sclerosis and frontotemporal dementia). The etiology of neurodegenerative diseases is often multifactorial, and the known risk factors include, in addition to genetic polymorphisms and age, some other possible causes, such as certain immune and metabolic conditions, endocrine pathologies, gender, socioeconomic or professional status, oxidative stress or inflammation, vitamin deficiencies and environmental factors (chemical exposure, metals). However, innovative strategies to elaborate suitable diagnostic and therapeutic approaches (aiming to at least delay or possibly even reverse disease progression) require further knowledge of the genetic and adaptive immunological characteristics of neurodegenerative diseases. (C) 2016 Elsevier Masson SAS. All rights reserved. |
DOI | 10.1016/j.neurol.2016.05.002 |